Neve Yarak, Israel — May 5, 2026 — Leads & Copy — Nexentis Technologies Inc. (NASDAQ: NXTS) announced that its subsidiary, MitoCareX Bio Ltd., has received official trademark registration from the United States Patent and Trademark Office (USPTO) for its MITOLINE™ algorithm platform.
MITOLINE™ is MitoCareX’s sequence analysis and alignment algorithm designed to prepare mitochondrial carrier proteins of the SLC25 family for reliable 3D homology modeling. The platform addresses the lack of solved 3D structures for most human mitochondrial carriers. It encodes the company’s algorithmic know-how to systematically align and annotate key amino acid sequences and specific residues, enabling the generation of robust 3D comparative models for target mitochondrial carriers using structural modeling tools.
David Palach, Chief Executive Officer of Nexentis Technologies, said securing U.S. trademark registration for MITOLINE™ is an important step in strengthening the distinct identity of their discovery engine as they scale MitoCareX within Nexentis. He added that they view MITOLINE™ as a strategic asset that differentiates their approach to mitochondrial biology and supports their goal of building a diversified pipeline of first-in-class small molecule programs.
MitoCareX focuses on developing therapies for cancers and inflammatory metabolic diseases by targeting proteins in the mitochondrial SLC25 carrier family. The company’s cloud-based discovery engine, leveraging MITOLINE™, supports the identification of small molecule scaffolds with the potential to impact hard-to-treat cancers and inflammatory metabolic conditions.
MitoCareX’s platform enables the characterization of substrate translocation pathways and binding pockets as functional targeting sites for virtual screening and hit optimization, which underpins the company’s precision oncology and inflammatory-metabolic pipeline. The platform also supports the validation of candidate molecules in mitochondrial and cellular in vitro systems that assess mitochondrial function, inflammatory signaling, and metabolic outputs.
Nexentis Technologies Inc. (NASDAQ: NXTS) owns 100% of MitoCareX Bio Ltd., a drug discovery company engaged in targeting cancer and inflammatory metabolic disease indications through the mitochondrial SLC25 protein family. Additionally, Nexentis adopted an investment strategy focused on European renewable energy assets utilizing a Ready to Build (RTB) business model. The Company is currently the lead investor in four solar projects across three European Union countries, all introduced by Solterra Renewable Energy Ltd., a wholly owned subsidiary of Solterra Energy Ltd.
Nexentis also controls approximately 98% of Save Foods Ltd., an Israeli company focused on post-harvest treatment technologies designed to reduce pathogen contamination in fruits and vegetables.
Source: Nexentis Technologies Inc.
